Table 1.
Baseline Characteristics
| Characteristic | No. (N = 37) | % |
|---|---|---|
| Age, years | ||
| Median | 64 | |
| Range | 42-81 | |
| Male sex | 26 | 70 |
| Race, white | ||
| Disease status | ||
| Relapsed | 21 | 57 |
| Refractory | 5 | 14 |
| Relapsed and refractory | 11 | 30 |
| No. of prior treatments | ||
| 1 | 11 | 30 |
| 2 | 8 | 22 |
| 3 | 7 | 19 |
| > 3 | 11 | 30 |
| Prior treatment | ||
| Chlorambucil, chlorambucil/prednisone, melphalan/prednisone | 6 | 16 |
| Cladribine, fludarabine, pentostatin | 17 | 46 |
| CHOP, CVP, cyclophosphamide, mitoxantrone, cyclophosphamide/mitoxantrone | 10 | 27 |
| Rituximab alone or with others | 29 | 78 |
| Bortezomib | 6 | 16 |
| Thalidomide or lenalidomide | 7 | 19 |
| Prednisone, dexamethasone, methylprednisolone single agents | 5 | 14 |
| Clinical trials agents* | 14 | 38 |
| Others† | 3 | 8 |
| ECOG PS | ||
| 0 | 30 | 81 |
| 1 | 7 | 19 |
| ISSWM | ||
| High risk | 6 | 16 |
| Intermediate risk | 11 | 30 |
| Low risk | 18 | 49 |
| NA‡ | 2 | 5 |
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; ECOG PS, Eastern Cooperative Oncology Group performance status; ISSWM, International Prognostic Scoring System in Waldenström Macroglobulinemia; NA, not applicable.
*
Clinical trials include sildenafil citrate and perifosine, RAD001, imatinib mesylate, and oblimersen sodium.
†
Others include radiation therapy, alemtuzumab, autologous bone marrow transplantation.
‡
Serum B2 was not measured in two patients at screening.